- Published on
Toxicology – Causes of Anion Gap Metabolic Acidosis
Alcohol (Ethanol)
Ethanol intoxication may lead to hypoglycemia, lactic acidosis, and alcoholic ketoacidosis, all of which contribute to an increased anion gap.
Aspirin (Salicylates)
Salicylate toxicity should be suspected in patients with anion gap metabolic acidosis and altered mental status. It typically produces a mixed disorder with metabolic acidosis and respiratory alkalosis due to direct stimulation of the respiratory center. It also increases renal loss of bicarbonate and potassium while promoting lactic and pyruvic acid formation.
Methanol
Methanol poisoning results in a high anion gap and hyperosmolar metabolic acidosis due to accumulation of formic acid, a toxic metabolite.
Ethylene Glycol
Commonly found in antifreeze, ethylene glycol is metabolized into glycolic, glyoxylic, and oxalic acids, producing a severe high anion gap metabolic acidosis.
Metformin
Metformin toxicity can lead to lactic acidosis by increasing production of lactate and other metabolic intermediates, particularly in patients with renal impairment or after contrast exposure.
Diabetic Ketoacidosis (DKA)
DKA occurs due to insulin deficiency, resulting in increased fatty acid metabolism and accumulation of ketoacids such as acetoacetate and β-hydroxybutyrate. Starvation and alcoholic ketosis can produce similar effects.
Uremia
Advanced kidney failure leads to accumulation of nitrogenous waste products and acids such as sulfuric and phosphoric acid, causing an anion gap metabolic acidosis.
Lactic Acidosis
Lactic acid accumulation from anaerobic metabolism is a common cause of anion gap acidosis and may result from hypoxia, hypoperfusion, toxins, or metabolic disorders.
Toluene
Toluene exposure, often through inhalation of solvents, increases production of organic acids such as benzoic and hippuric acid and may also cause renal tubular acidosis with chronic use.
Carbamazepine
Overdose of this antiepileptic drug can lead to metabolic acidosis along with hyperglycemia, ketonuria, altered mental status, seizures, and coma.
Isoniazid (INH)
Isoniazid toxicity can result in lactic acidosis, often accompanied by seizures and altered mental status.
Iron
Iron overdose contributes to metabolic acidosis through hypovolemia, hypotension, and the release of hydrogen ions during its metabolic conversion.
Paraldehyde
This older sedative-hypnotic agent, historically used for seizures, can contribute to anion gap metabolic acidosis in toxic exposures.
Alcohol (Ethanol)
Ethanol intoxication may lead to hypoglycemia, lactic acidosis, and alcoholic ketoacidosis, all of which contribute to an increased anion gap.
Aspirin (Salicylates)
Salicylate toxicity should be suspected in patients with anion gap metabolic acidosis and altered mental status. It typically produces a mixed disorder with metabolic acidosis and respiratory alkalosis due to direct stimulation of the respiratory center. It also increases renal loss of bicarbonate and potassium while promoting lactic and pyruvic acid formation.
Methanol
Methanol poisoning results in a high anion gap and hyperosmolar metabolic acidosis due to accumulation of formic acid, a toxic metabolite.
Ethylene Glycol
Commonly found in antifreeze, ethylene glycol is metabolized into glycolic, glyoxylic, and oxalic acids, producing a severe high anion gap metabolic acidosis.
Metformin
Metformin toxicity can lead to lactic acidosis by increasing production of lactate and other metabolic intermediates, particularly in patients with renal impairment or after contrast exposure.
Diabetic Ketoacidosis (DKA)
DKA occurs due to insulin deficiency, resulting in increased fatty acid metabolism and accumulation of ketoacids such as acetoacetate and β-hydroxybutyrate. Starvation and alcoholic ketosis can produce similar effects.
Uremia
Advanced kidney failure leads to accumulation of nitrogenous waste products and acids such as sulfuric and phosphoric acid, causing an anion gap metabolic acidosis.
Lactic Acidosis
Lactic acid accumulation from anaerobic metabolism is a common cause of anion gap acidosis and may result from hypoxia, hypoperfusion, toxins, or metabolic disorders.
Toluene
Toluene exposure, often through inhalation of solvents, increases production of organic acids such as benzoic and hippuric acid and may also cause renal tubular acidosis with chronic use.
Carbamazepine
Overdose of this antiepileptic drug can lead to metabolic acidosis along with hyperglycemia, ketonuria, altered mental status, seizures, and coma.
Isoniazid (INH)
Isoniazid toxicity can result in lactic acidosis, often accompanied by seizures and altered mental status.
Iron
Iron overdose contributes to metabolic acidosis through hypovolemia, hypotension, and the release of hydrogen ions during its metabolic conversion.
Paraldehyde
This older sedative-hypnotic agent, historically used for seizures, can contribute to anion gap metabolic acidosis in toxic exposures.
- Published on
Toxicology – Toxins Causing Cyanosis
Ergotamine
Ergot compounds can lead to acrocyanosis due to intense vasoconstriction, resembling a secondary Raynaud phenomenon affecting peripheral circulation.
Phenazopyridine
This urinary tract analgesic can induce methemoglobinemia, impairing oxygen delivery and resulting in cyanosis.
Aniline
Aniline, a chemical used in the production of dyes and polyurethane, can cause both methemoglobinemia and hemolytic anemia, contributing to cyanotic discoloration.
Dapsone
Dapsone, used in the treatment of leprosy and for Pneumocystis jirovecii pneumonia prophylaxis, is a well-known cause of methemoglobinemia.
Nitrates
Nitrates, sometimes present in contaminated well water, can induce methemoglobinemia, particularly in infants.
Nitrites
Nitrites are used therapeutically to induce methemoglobinemia in cyanide poisoning but may also be abused recreationally for their vasodilatory effects, leading to cyanosis.
Asphyxia
Conditions causing hypoxemia or impaired oxygen delivery increase levels of deoxygenated hemoglobin, resulting in cyanosis.
Treatment
Methylene blue is the treatment of choice for methemoglobinemia. It acts as a reducing agent, converting methemoglobin back to functional hemoglobin, and is typically administered at a dose of 1–2 mg/kg intravenously over 5 minutes.
Ergotamine
Ergot compounds can lead to acrocyanosis due to intense vasoconstriction, resembling a secondary Raynaud phenomenon affecting peripheral circulation.
Phenazopyridine
This urinary tract analgesic can induce methemoglobinemia, impairing oxygen delivery and resulting in cyanosis.
Aniline
Aniline, a chemical used in the production of dyes and polyurethane, can cause both methemoglobinemia and hemolytic anemia, contributing to cyanotic discoloration.
Dapsone
Dapsone, used in the treatment of leprosy and for Pneumocystis jirovecii pneumonia prophylaxis, is a well-known cause of methemoglobinemia.
Nitrates
Nitrates, sometimes present in contaminated well water, can induce methemoglobinemia, particularly in infants.
Nitrites
Nitrites are used therapeutically to induce methemoglobinemia in cyanide poisoning but may also be abused recreationally for their vasodilatory effects, leading to cyanosis.
Asphyxia
Conditions causing hypoxemia or impaired oxygen delivery increase levels of deoxygenated hemoglobin, resulting in cyanosis.
Treatment
Methylene blue is the treatment of choice for methemoglobinemia. It acts as a reducing agent, converting methemoglobin back to functional hemoglobin, and is typically administered at a dose of 1–2 mg/kg intravenously over 5 minutes.
- Published on
Toxicology – Toxins Causing Erythema
Carbon Monoxide
Carbon monoxide poisoning may produce the classic “cherry red” skin appearance, although this is a late and often postmortem finding rather than a reliable early clinical sign.
Cyanide
Cyanide toxicity can cause skin erythema due to elevated levels of oxygenated hemoglobin in the venous system. Additionally, hydroxocobalamin, a common antidote, can itself produce noticeable skin redness.
Chinese Restaurant Syndrome (MSG Reaction)
This condition is associated with ingestion of monosodium glutamate (MSG) and may present with flushing, chest discomfort, palpitations, headache, perioral tingling, facial swelling, and sweating.
Scombroid Poisoning
Scombroid poisoning results from ingestion of histamine-rich spoiled fish, leading to vasodilation and prominent skin flushing.
Anticholinergics
Erythema is a hallmark feature of anticholinergic toxicity, often described as “red as a beet” in the classic toxidrome.
Niacin
Niacin, commonly used to manage lipid levels, frequently causes flushing even at therapeutic doses. This effect can be reduced by taking aspirin beforehand or dosing at night.
Disulfiram Reaction
This reaction occurs when aldehyde dehydrogenase is inhibited by agents such as disulfiram, metronidazole, tolbutamide, or cefotetan. When alcohol is consumed, acetaldehyde accumulates, leading to flushing along with nausea, vomiting, tachycardia, shortness of breath, headache, and confusion.
Carbon Monoxide
Carbon monoxide poisoning may produce the classic “cherry red” skin appearance, although this is a late and often postmortem finding rather than a reliable early clinical sign.
Cyanide
Cyanide toxicity can cause skin erythema due to elevated levels of oxygenated hemoglobin in the venous system. Additionally, hydroxocobalamin, a common antidote, can itself produce noticeable skin redness.
Chinese Restaurant Syndrome (MSG Reaction)
This condition is associated with ingestion of monosodium glutamate (MSG) and may present with flushing, chest discomfort, palpitations, headache, perioral tingling, facial swelling, and sweating.
Scombroid Poisoning
Scombroid poisoning results from ingestion of histamine-rich spoiled fish, leading to vasodilation and prominent skin flushing.
Anticholinergics
Erythema is a hallmark feature of anticholinergic toxicity, often described as “red as a beet” in the classic toxidrome.
Niacin
Niacin, commonly used to manage lipid levels, frequently causes flushing even at therapeutic doses. This effect can be reduced by taking aspirin beforehand or dosing at night.
Disulfiram Reaction
This reaction occurs when aldehyde dehydrogenase is inhibited by agents such as disulfiram, metronidazole, tolbutamide, or cefotetan. When alcohol is consumed, acetaldehyde accumulates, leading to flushing along with nausea, vomiting, tachycardia, shortness of breath, headache, and confusion.
- Published on
Toxicology – Nystagmus-Inducing Toxins
Sedative–Hypnotics
Medications in this class commonly produce nystagmus as part of central nervous system depression.
Alcohols (Ethanol, Methanol, Ethylene Glycol, Isopropanol)
All alcohols can induce nystagmus. Ethanol is particularly associated with horizontal and downbeat nystagmus and is often assessed clinically using the horizontal gaze nystagmus test.
Phencyclidine and Dissociatives
Dissociative agents such as PCP, ketamine, and dextromethorphan can produce a characteristic rotatory nystagmus.
Phenytoin
Phenytoin toxicity is associated with horizontal and sometimes upbeat nystagmus.
Carbamazepine (Tegretol)
Carbamazepine can cause both horizontal and downbeat nystagmus.
Lithium
Lithium toxicity may lead to downbeat nystagmus.
Solvents (Inhalants)
Exposure to inhaled solvents has been associated with positional nystagmus, with severity correlating to the degree of exposure.
Thiamine Deficiency (Wernicke Encephalopathy)
Thiamine deficiency can result in Wernicke encephalopathy, characterized by ataxia, confusion, ophthalmoplegia, and nystagmus.
Overview
Nystagmus is an involuntary, rhythmic oscillation of the eyes that may occur in toxicologic conditions. It can present as horizontal (side-to-side), vertical (upbeat or downbeat), or rotatory movement. Horizontal nystagmus is the most common and is best observed during lateral gaze. Alcohol intoxication frequently produces nystagmus, which is often assessed in clinical and roadside settings. Certain agents such as anticonvulsants and lithium may produce vertical nystagmus, while phenytoin has been associated with upbeat nystagmus and PCP with rotatory nystagmus.
Sedative–Hypnotics
Medications in this class commonly produce nystagmus as part of central nervous system depression.
Alcohols (Ethanol, Methanol, Ethylene Glycol, Isopropanol)
All alcohols can induce nystagmus. Ethanol is particularly associated with horizontal and downbeat nystagmus and is often assessed clinically using the horizontal gaze nystagmus test.
Phencyclidine and Dissociatives
Dissociative agents such as PCP, ketamine, and dextromethorphan can produce a characteristic rotatory nystagmus.
Phenytoin
Phenytoin toxicity is associated with horizontal and sometimes upbeat nystagmus.
Carbamazepine (Tegretol)
Carbamazepine can cause both horizontal and downbeat nystagmus.
Lithium
Lithium toxicity may lead to downbeat nystagmus.
Solvents (Inhalants)
Exposure to inhaled solvents has been associated with positional nystagmus, with severity correlating to the degree of exposure.
Thiamine Deficiency (Wernicke Encephalopathy)
Thiamine deficiency can result in Wernicke encephalopathy, characterized by ataxia, confusion, ophthalmoplegia, and nystagmus.
Overview
Nystagmus is an involuntary, rhythmic oscillation of the eyes that may occur in toxicologic conditions. It can present as horizontal (side-to-side), vertical (upbeat or downbeat), or rotatory movement. Horizontal nystagmus is the most common and is best observed during lateral gaze. Alcohol intoxication frequently produces nystagmus, which is often assessed in clinical and roadside settings. Certain agents such as anticonvulsants and lithium may produce vertical nystagmus, while phenytoin has been associated with upbeat nystagmus and PCP with rotatory nystagmus.
- Published on
Toxicology – Drugs Causing Tachycardia
Cocaine (Freebase)
Cocaine produces strong sympathomimetic effects by blocking the reuptake of serotonin, dopamine, and norepinephrine, leading to increased heart rate and blood pressure.
Amphetamines
Amphetamines stimulate the release of catecholamines from presynaptic nerve terminals, resulting in marked tachycardia and hypertension.
Sympathomimetics
This group of drugs elevates heart rate and blood pressure by increasing catecholamine release, decreasing reuptake, or inhibiting metabolism.
Anticholinergics
Anticholinergic agents inhibit parasympathetic activity, causing an increase in heart rate and often accompanying hypertension.
Antihistamines
Many antihistamines possess anticholinergic properties, which can lead to tachycardia as part of their toxic effects.
Theophylline (Methylxanthines)
Theophylline acts as an adenosine receptor antagonist, β-agonist, and phosphodiesterase inhibitor, all of which contribute to increased heart rate and potential arrhythmias.
Thyroid Hormone
Excess thyroid hormone elevates metabolic rate and enhances sensitivity to catecholamines, leading to tachycardia.
Solvents (Inhalants)
Inhaled solvents may displace oxygen in the lungs, causing hypoxemia and reflex tachycardia. They can also sensitize the myocardium to catecholamines, increasing the risk of fatal arrhythmias.
Fever
An increase in body temperature raises basal metabolic rate, which in turn increases heart rate.
Treatment
Benzodiazepines are the first-line treatment for undifferentiated tachycardia in toxicologic settings. Intravenous fluids should be administered in cases of hypovolemia, and active cooling measures should be initiated for patients with hyperthermia.
Cocaine (Freebase)
Cocaine produces strong sympathomimetic effects by blocking the reuptake of serotonin, dopamine, and norepinephrine, leading to increased heart rate and blood pressure.
Amphetamines
Amphetamines stimulate the release of catecholamines from presynaptic nerve terminals, resulting in marked tachycardia and hypertension.
Sympathomimetics
This group of drugs elevates heart rate and blood pressure by increasing catecholamine release, decreasing reuptake, or inhibiting metabolism.
Anticholinergics
Anticholinergic agents inhibit parasympathetic activity, causing an increase in heart rate and often accompanying hypertension.
Antihistamines
Many antihistamines possess anticholinergic properties, which can lead to tachycardia as part of their toxic effects.
Theophylline (Methylxanthines)
Theophylline acts as an adenosine receptor antagonist, β-agonist, and phosphodiesterase inhibitor, all of which contribute to increased heart rate and potential arrhythmias.
Thyroid Hormone
Excess thyroid hormone elevates metabolic rate and enhances sensitivity to catecholamines, leading to tachycardia.
Solvents (Inhalants)
Inhaled solvents may displace oxygen in the lungs, causing hypoxemia and reflex tachycardia. They can also sensitize the myocardium to catecholamines, increasing the risk of fatal arrhythmias.
Fever
An increase in body temperature raises basal metabolic rate, which in turn increases heart rate.
Treatment
Benzodiazepines are the first-line treatment for undifferentiated tachycardia in toxicologic settings. Intravenous fluids should be administered in cases of hypovolemia, and active cooling measures should be initiated for patients with hyperthermia.
- Published on
Toxicology – Drugs Causing Bradycardia
Beta-Blockers (e.g., Propranolol)
Beta-blockers reduce sinoatrial (SA) and atrioventricular (AV) nodal conduction, leading to decreased heart rate and, in severe cases, heart block.
Opiates (Poppies)
Opiates increase vagal tone and exert a depressant effect on SA and AV nodal conduction, contributing to bradycardia.
Anticholinesterase Inhibitors
By inhibiting acetylcholinesterase, these agents increase acetylcholine levels, producing a cholinergic toxidrome in which bradycardia is a prominent feature.
Clonidine
Clonidine is a central α₂ receptor agonist that can cause bradycardia along with hypotension and respiratory depression.
Calcium Channel Blockers
These medications impair SA and AV nodal conduction, resulting in decreased heart rate and potential heart block.
Digoxin
Digoxin increases vagal tone while slowing conduction through the SA and AV nodes, leading to bradycardia despite its positive inotropic effects.
Ethanol
At high doses, ethanol can depress cardiac function and contribute to bradycardia.
Treatment
Atropine may be administered to counteract increased vagal tone and raise heart rate. If ineffective, external pacing should be considered. Definitive management involves identifying the causative toxin and administering the appropriate antidote or targeted therapy.
Beta-Blockers (e.g., Propranolol)
Beta-blockers reduce sinoatrial (SA) and atrioventricular (AV) nodal conduction, leading to decreased heart rate and, in severe cases, heart block.
Opiates (Poppies)
Opiates increase vagal tone and exert a depressant effect on SA and AV nodal conduction, contributing to bradycardia.
Anticholinesterase Inhibitors
By inhibiting acetylcholinesterase, these agents increase acetylcholine levels, producing a cholinergic toxidrome in which bradycardia is a prominent feature.
Clonidine
Clonidine is a central α₂ receptor agonist that can cause bradycardia along with hypotension and respiratory depression.
Calcium Channel Blockers
These medications impair SA and AV nodal conduction, resulting in decreased heart rate and potential heart block.
Digoxin
Digoxin increases vagal tone while slowing conduction through the SA and AV nodes, leading to bradycardia despite its positive inotropic effects.
Ethanol
At high doses, ethanol can depress cardiac function and contribute to bradycardia.
Treatment
Atropine may be administered to counteract increased vagal tone and raise heart rate. If ineffective, external pacing should be considered. Definitive management involves identifying the causative toxin and administering the appropriate antidote or targeted therapy.
- Published on
Toxicology – Drugs Causing Hypoventilation
Opiates
Opiates are the most significant contributors to respiratory depression among toxicologic agents. They suppress the brainstem respiratory center, leading to decreased respiratory rate and depth. Reversal with naloxone is effective but should be carefully titrated to avoid precipitating acute withdrawal.
Sedative–Hypnotics
This class of central nervous system depressants reduces respiratory drive in overdose situations, potentially leading to hypoventilation and respiratory failure.
Liquor (Ethanol)
At very high concentrations, ethanol can cause marked central nervous system depression, resulting in clinically significant respiratory suppression.
Weed (Cannabinoids)
Cannabinoid receptor agonists such as marijuana generally have mild respiratory effects. However, slight reductions in respiratory rate may occur as part of overall central nervous system depression.
Treatment
In patients with decreased consciousness, central nervous system depression, or inadequate ventilation, airway protection with endotracheal intubation is essential. Opiate toxicity can be reversed with naloxone, and continuous infusion may be required due to its shorter duration of action compared to many opioids. Flumazenil may reverse certain sedative–hypnotics like benzodiazepines, but it must be used cautiously as it can trigger withdrawal seizures or status epilepticus in dependent individuals.
Opiates
Opiates are the most significant contributors to respiratory depression among toxicologic agents. They suppress the brainstem respiratory center, leading to decreased respiratory rate and depth. Reversal with naloxone is effective but should be carefully titrated to avoid precipitating acute withdrawal.
Sedative–Hypnotics
This class of central nervous system depressants reduces respiratory drive in overdose situations, potentially leading to hypoventilation and respiratory failure.
Liquor (Ethanol)
At very high concentrations, ethanol can cause marked central nervous system depression, resulting in clinically significant respiratory suppression.
Weed (Cannabinoids)
Cannabinoid receptor agonists such as marijuana generally have mild respiratory effects. However, slight reductions in respiratory rate may occur as part of overall central nervous system depression.
Treatment
In patients with decreased consciousness, central nervous system depression, or inadequate ventilation, airway protection with endotracheal intubation is essential. Opiate toxicity can be reversed with naloxone, and continuous infusion may be required due to its shorter duration of action compared to many opioids. Flumazenil may reverse certain sedative–hypnotics like benzodiazepines, but it must be used cautiously as it can trigger withdrawal seizures or status epilepticus in dependent individuals.
- Published on
Infectious disease and microbiology – Pericarditis
Pericarditis is an inflammatory condition of the pericardium, the sac surrounding the heart, and can result from a wide range of infectious (viral, bacterial, fungal, protozoal) and noninfectious causes. In many cases, especially when no specific pathogen is identified, it is presumed to be viral or idiopathic, often involving an immune-mediated mechanism.
The condition is relatively common in clinical practice, accounting for about 5% of emergency visits for chest pain, though it occurs in only about 0.1% of hospitalized patients. Bacterial pericarditis is much rarer but more severe. There is no specific prevention for idiopathic cases, but early diagnosis and treatment can reduce complications and the need for surgical intervention.
Pathophysiologically, pericarditis may result from direct infection of the pericardium, as seen in bacterial cases, or from an autoimmune response, particularly in idiopathic or viral forms. Tuberculous pericarditis involves immune activation with CD4 lymphocytes and interferon-gamma, while viral infections lead to lymphocytic inflammation of the pericardium.
A wide variety of pathogens can cause pericarditis. Viruses are the most common, especially Coxsackie A and B, along with herpes viruses, influenza, adenovirus, HIV, and others. Bacterial causes often arise from nearby infections like pneumonia or from postoperative or hospital-acquired infections, with organisms such as Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative bacteria. Less commonly, fungi (e.g., Candida, Histoplasma) and protozoa (e.g., Toxoplasma, Entamoeba histolytica) are involved, typically in disseminated disease.
Clinically, patients usually present with sharp, retrosternal chest pain and fever, with pain often relieved by sitting forward, which is a classic feature. Viral prodromal symptoms may be present. In bacterial cases, chest pain may be less prominent. Other findings include tachypnea and tachycardia, and in severe cases, progression to cardiac tamponade. On examination, a pericardial friction rub is characteristic, and signs such as pulsus paradoxus and decreased heart sounds may indicate significant effusion.
Diagnosis relies heavily on electrocardiography (ECG), which typically shows diffuse ST-segment elevation and PR depression, making it one of the most important diagnostic tools. Laboratory findings may include elevated white blood cells and inflammatory markers, and sometimes elevated cardiac troponins. Imaging such as chest X-ray, CT, MRI, or echocardiography helps assess pericardial effusion and structural involvement. Pericardiocentesis or biopsy may be necessary for diagnosis and to relieve tamponade, with fluid analysis aiding in identifying the cause.
Management depends on the underlying etiology. Most cases are treated with nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or indomethacin, along with colchicine, which reduces symptoms and recurrence. Steroids are generally avoided except in specific situations like tuberculous pericarditis. If a specific pathogen is identified, targeted therapy is required—for example, antivirals (e.g., acyclovir, ganciclovir), antibiotics for bacterial causes, or antituberculous therapy. Supportive measures include bed rest and gastric protection when using NSAIDs.
Severe complications such as cardiac tamponade require urgent intervention with pericardiocentesis, while purulent or constrictive pericarditis may necessitate surgical procedures like pericardiotomy or pericardiectomy. Hospitalization is indicated in high-risk patients, including those with fever, large effusions, immunosuppression, or failure of initial therapy.
The prognosis is generally excellent in idiopathic or viral pericarditis, with recovery in most patients. However, outcomes are worse in tuberculous or untreated bacterial pericarditis, which can be fatal. Important complications include recurrence, constrictive pericarditis, and cardiac tamponade, all of which require careful monitoring and follow-up, often with repeat echocardiography.
Pericarditis is an inflammatory condition of the pericardium, the sac surrounding the heart, and can result from a wide range of infectious (viral, bacterial, fungal, protozoal) and noninfectious causes. In many cases, especially when no specific pathogen is identified, it is presumed to be viral or idiopathic, often involving an immune-mediated mechanism.
The condition is relatively common in clinical practice, accounting for about 5% of emergency visits for chest pain, though it occurs in only about 0.1% of hospitalized patients. Bacterial pericarditis is much rarer but more severe. There is no specific prevention for idiopathic cases, but early diagnosis and treatment can reduce complications and the need for surgical intervention.
Pathophysiologically, pericarditis may result from direct infection of the pericardium, as seen in bacterial cases, or from an autoimmune response, particularly in idiopathic or viral forms. Tuberculous pericarditis involves immune activation with CD4 lymphocytes and interferon-gamma, while viral infections lead to lymphocytic inflammation of the pericardium.
A wide variety of pathogens can cause pericarditis. Viruses are the most common, especially Coxsackie A and B, along with herpes viruses, influenza, adenovirus, HIV, and others. Bacterial causes often arise from nearby infections like pneumonia or from postoperative or hospital-acquired infections, with organisms such as Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative bacteria. Less commonly, fungi (e.g., Candida, Histoplasma) and protozoa (e.g., Toxoplasma, Entamoeba histolytica) are involved, typically in disseminated disease.
Clinically, patients usually present with sharp, retrosternal chest pain and fever, with pain often relieved by sitting forward, which is a classic feature. Viral prodromal symptoms may be present. In bacterial cases, chest pain may be less prominent. Other findings include tachypnea and tachycardia, and in severe cases, progression to cardiac tamponade. On examination, a pericardial friction rub is characteristic, and signs such as pulsus paradoxus and decreased heart sounds may indicate significant effusion.
Diagnosis relies heavily on electrocardiography (ECG), which typically shows diffuse ST-segment elevation and PR depression, making it one of the most important diagnostic tools. Laboratory findings may include elevated white blood cells and inflammatory markers, and sometimes elevated cardiac troponins. Imaging such as chest X-ray, CT, MRI, or echocardiography helps assess pericardial effusion and structural involvement. Pericardiocentesis or biopsy may be necessary for diagnosis and to relieve tamponade, with fluid analysis aiding in identifying the cause.
Management depends on the underlying etiology. Most cases are treated with nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or indomethacin, along with colchicine, which reduces symptoms and recurrence. Steroids are generally avoided except in specific situations like tuberculous pericarditis. If a specific pathogen is identified, targeted therapy is required—for example, antivirals (e.g., acyclovir, ganciclovir), antibiotics for bacterial causes, or antituberculous therapy. Supportive measures include bed rest and gastric protection when using NSAIDs.
Severe complications such as cardiac tamponade require urgent intervention with pericardiocentesis, while purulent or constrictive pericarditis may necessitate surgical procedures like pericardiotomy or pericardiectomy. Hospitalization is indicated in high-risk patients, including those with fever, large effusions, immunosuppression, or failure of initial therapy.
The prognosis is generally excellent in idiopathic or viral pericarditis, with recovery in most patients. However, outcomes are worse in tuberculous or untreated bacterial pericarditis, which can be fatal. Important complications include recurrence, constrictive pericarditis, and cardiac tamponade, all of which require careful monitoring and follow-up, often with repeat echocardiography.
- Published on
Infectious disease and microbiology – Parvovirus infection
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
- Published on
Infectious disease and microbiology – Otitis media
Otitis media refers to inflammation of the middle ear, involving the mucosa and periosteum, and encompasses several clinical forms including acute otitis media (AOM), recurrent AOM, otitis media with effusion (OME), and chronic suppurative otitis media (CSOM). Acute otitis media is defined by the presence of middle-ear fluid along with signs of acute infection, whereas OME involves persistent fluid without active infection, and CSOM is characterized by chronic ear discharge through a perforated tympanic membrane, sometimes associated with cholesteatoma.
This condition is extremely common in children, with more than two-thirds experiencing at least one episode before age 3, and a peak incidence between 6–24 months. It is far less common in adults. Risk factors include eustachian tube dysfunction (often following viral upper respiratory infections), daycare attendance, passive smoking, congenital anomalies (e.g., cleft palate), immunodeficiency, and early age of first infection. Preventive strategies emphasize vaccination (pneumococcal, Haemophilus influenzae, influenza), breastfeeding, and appropriate early treatment.
The pathophysiology centers on eustachian tube dysfunction, leading to fluid accumulation in the middle ear, which serves as a medium for microbial growth. Viral infections often precede bacterial infection by causing mucosal swelling and obstruction.
The etiology varies by age and clinical form. In children, the most common pathogens are Streptococcus pneumoniae, Haemophilus influenzae (mostly nontypable), and Moraxella catarrhalis. Other organisms include group A streptococci and Staphylococcus aureus. In neonates, group B streptococci and gram-negative bacilli are important, while in adults, H. influenzae and S. pneumoniae predominate. Chronic suppurative otitis media often involves Pseudomonas aeruginosa, S. aureus, enteric gram-negative bacilli, and anaerobes.
Clinically, acute otitis media presents with ear pain, fever, and hearing loss, while infants may show nonspecific symptoms such as irritability or feeding difficulties. OME is often asymptomatic but may cause a feeling of fullness or mild hearing loss, whereas CSOM presents with chronic purulent discharge and hearing impairment.
Diagnosis relies on otoscopic examination, which typically shows a bulging, erythematous, and immobile tympanic membrane in acute disease, while OME shows a dull, hypomobile membrane without bulging. Tympanometry and hearing tests can help confirm middle-ear fluid and assess hearing loss. In complicated or chronic cases, CT imaging may be required to evaluate for cholesteatoma or mastoid involvement.
Treatment depends on the clinical scenario. Amoxicillin remains the first-line therapy for most cases of acute otitis media, with alternatives such as amoxicillin-clavulanate or cephalosporins used in resistant or recurrent cases. Macrolides or TMP-SMX may be used in penicillin-allergic patients. A watchful waiting approach may be appropriate in selected children over 6 months with mild symptoms. OME generally does not benefit from antibiotics, antihistamines, or decongestants, and is often managed with observation. CSOM requires topical antibiotics and often surgical intervention, especially if cholesteatoma is present.
Surgical options include tympanostomy tube placement for persistent effusion or recurrent infections, and adenoidectomy in selected cases. Pain control with analgesics is essential in all patients regardless of antibiotic use.
The prognosis for acute otitis media is excellent with appropriate treatment. However, complications can occur, particularly in untreated or severe cases, including mastoiditis, hearing loss, facial nerve paralysis, labyrinthitis, and intracranial infections such as meningitis or brain abscess. Careful follow-up is especially important in children with persistent effusion to prevent long-term hearing and developmental issues.
Otitis media refers to inflammation of the middle ear, involving the mucosa and periosteum, and encompasses several clinical forms including acute otitis media (AOM), recurrent AOM, otitis media with effusion (OME), and chronic suppurative otitis media (CSOM). Acute otitis media is defined by the presence of middle-ear fluid along with signs of acute infection, whereas OME involves persistent fluid without active infection, and CSOM is characterized by chronic ear discharge through a perforated tympanic membrane, sometimes associated with cholesteatoma.
This condition is extremely common in children, with more than two-thirds experiencing at least one episode before age 3, and a peak incidence between 6–24 months. It is far less common in adults. Risk factors include eustachian tube dysfunction (often following viral upper respiratory infections), daycare attendance, passive smoking, congenital anomalies (e.g., cleft palate), immunodeficiency, and early age of first infection. Preventive strategies emphasize vaccination (pneumococcal, Haemophilus influenzae, influenza), breastfeeding, and appropriate early treatment.
The pathophysiology centers on eustachian tube dysfunction, leading to fluid accumulation in the middle ear, which serves as a medium for microbial growth. Viral infections often precede bacterial infection by causing mucosal swelling and obstruction.
The etiology varies by age and clinical form. In children, the most common pathogens are Streptococcus pneumoniae, Haemophilus influenzae (mostly nontypable), and Moraxella catarrhalis. Other organisms include group A streptococci and Staphylococcus aureus. In neonates, group B streptococci and gram-negative bacilli are important, while in adults, H. influenzae and S. pneumoniae predominate. Chronic suppurative otitis media often involves Pseudomonas aeruginosa, S. aureus, enteric gram-negative bacilli, and anaerobes.
Clinically, acute otitis media presents with ear pain, fever, and hearing loss, while infants may show nonspecific symptoms such as irritability or feeding difficulties. OME is often asymptomatic but may cause a feeling of fullness or mild hearing loss, whereas CSOM presents with chronic purulent discharge and hearing impairment.
Diagnosis relies on otoscopic examination, which typically shows a bulging, erythematous, and immobile tympanic membrane in acute disease, while OME shows a dull, hypomobile membrane without bulging. Tympanometry and hearing tests can help confirm middle-ear fluid and assess hearing loss. In complicated or chronic cases, CT imaging may be required to evaluate for cholesteatoma or mastoid involvement.
Treatment depends on the clinical scenario. Amoxicillin remains the first-line therapy for most cases of acute otitis media, with alternatives such as amoxicillin-clavulanate or cephalosporins used in resistant or recurrent cases. Macrolides or TMP-SMX may be used in penicillin-allergic patients. A watchful waiting approach may be appropriate in selected children over 6 months with mild symptoms. OME generally does not benefit from antibiotics, antihistamines, or decongestants, and is often managed with observation. CSOM requires topical antibiotics and often surgical intervention, especially if cholesteatoma is present.
Surgical options include tympanostomy tube placement for persistent effusion or recurrent infections, and adenoidectomy in selected cases. Pain control with analgesics is essential in all patients regardless of antibiotic use.
The prognosis for acute otitis media is excellent with appropriate treatment. However, complications can occur, particularly in untreated or severe cases, including mastoiditis, hearing loss, facial nerve paralysis, labyrinthitis, and intracranial infections such as meningitis or brain abscess. Careful follow-up is especially important in children with persistent effusion to prevent long-term hearing and developmental issues.
